MECYSTEINE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C4H9NO2S.ClH
Molecular Weight	171.646
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.COC(=O)[C@@H](N)CS

InChI

InChIKey=WHOHXJZQBJXAKL-DFWYDOINSA-N

InChI=1S/C4H9NO2S.ClH/c1-7-4(6)3(5)2-8;/h3,8H,2,5H2,1H3;1H/t3-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H9NO2S
Molecular Weight	135.185
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2033689.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22908983 | https://www.ncbi.nlm.nih.gov/pubmed/6185664

Mecysteine is used as a mucolytic in respiratory disorders associated with productive cough. Mecysteine is known as a mucolytic agent, it breaks down mucus. It works by breaking some of the chemical bonds between the molecules in mucus. It is given orally in a usual dose of 200 mg three times daily before meals reduced to 200 mg twice daily after 6 weeks. A rapid clinical effect can be achieved by giving 200 mg four times daily for the first 2 days. Mecysteine has also been given by inhalation.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mucus glycoproteins 2 Target ID: Mucus glycoproteins Sources: https://www.ncbi.nlm.nih.gov/pubmed/6185664	Modulator 828

Conditions

Condition	Modality	Highest Phase	Product
Chronic obstructive pulmonary disease 174 Sources: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2033689.pdf http://www.ndrugs.com/?s=visclair http://www.netdoctor.co.uk/medicines/lungs/a7749/visclair/	Primary	Approved 8429	VISCLAIR Approved Use Visclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm.
Sinusitis 26 Sources: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1381465588312.pdf	Primary	Approved 8429	VISCLAIR Approved Use Visclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm.
Secretory otitis 2 Sources: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1381465588312.pdf	Primary	Approved 8429	VISCLAIR Approved Use Visclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm.

PubMed

Title	Date	PubMed
Mild and highly chemoselective oxidation of thioethers mediated by Sc(OTf)3.	2003 Feb 6	12556160
Effect of five cysteine-containing compounds on three lipogenic enzymes in Balb/cA mice consuming a high saturated fat diet.	2004 Sep	15669759
Removal of toxic metal-ion pollutants from water by using chemically modified carbon powders.	2006 Oct 20	17441101
Facile discrimination of aldose enantiomers by reversed-phase HPLC.	2007 Jun	17541189
Neuroimaging in the clinical diagnosis of dementia: observations from a memory disorders clinic.	2010 Aug	20670380

Patents

Sample Use Guides

In Vivo Use Guide

It is given orally in a usual dose of 200 mg three times daily before meals reduced to 200 mg twice daily after 6 weeks. A rapid clinical effect can be achieved by giving 200 mg four times daily for the first 2 days.

Route of Administration: Oral

In Vitro Use Guide

The effects of L-cysteine methyl ester (Mecysteine) on behavior of mucus glycoproteins in canine tracheal secretory cells were investigated histologically and histochemically. Low concentrations (10(-7) and 10(-6)M) of L-cysteine methyl ester produced, as histological changes, decreases in the total goblet cell number and the thickness of the acini of submucosal glands, and an increase in the acinar inner diameter. On the other hand, L-cysteine methyl ester at 10(-5) and 10(-4)M produced an increase in the thickness of the acini and a slight decrease in the acinar inner diameter.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:11:36 GMT 2023` Edited by `admin` on `Fri Dec 15 15:11:36 GMT 2023`
Record UNII	33RG619160
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MECYSTEINE HYDROCHLORIDE

Common Name

English

MECYSTEINE HYDROCHLORIDE [MI]

Common Name

English

MECYSTEINE HYDROCHLORIDE [MART.]

Common Name

English

L-CYSTEINE METHYL ESTER HYDROCHLORIDE

Systematic Name

English

METHYL (R)-2-AMINO-3-MERCAPTOPROPANOATE HYDROCHLORIDE

Systematic Name

English

ACDRILE

Common Name

English

METHYL L-CYSTEINE HYDROCHLORIDE [JAN]

Common Name

English

Mecysteine hydrochloride [WHO-DD]

Common Name

English

ACTIOL

Common Name

English

L-CYSTEINE, METHYL ESTER, HYDROCHLORIDE

Systematic Name

English

NSC-161611

Code

English

METHYL L-CYSTEINE HYDROCHLORIDE

Systematic Name

English

Code System Code Type Description

MESH

C017507